SCHEMBL25978744

SCHEMBL25978744

c1ccc(-c2ccc(N(c3cccc(-c4ccccc4)c3)c3ccc4oc5cc(-c6nc(-c7ccccc7)nc(-c7ccccc7)n6)ccc5c4c3)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HCRTR1 O43613 1/20 0.34
MMP12 P39900 2/20 0.34
MMP13 P45452 1/20 0.34
PGR P06401 1/20 0.33
MEN1 O00255 4/20 0.33
MAPT P10636 4/20 0.33
KMT2A Q03164 4/20 0.33
PLA2G2A P14555 3/20 0.33
PLA2G4A P47712 3/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 3/20 0.33
CHEK2 O96017 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.32
LMNA P02545 2/20 0.32
GLA P06280 2/20 0.32
TBK1 Q9UHD2 1/20 0.32
KDM1A O60341 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25978683 1.00 GAA (0.35) GAAL3MBTL1HCRTR1MMP12MMP13
SCHEMBL25978745 0.99 GAA (0.36) GAAL3MBTL1HCRTR1MMP12MMP13
SCHEMBL26779147 0.98 GAA (0.35) GAAL3MBTL1HCRTR1MMP12MMP13
SCHEMBL26779167 0.98 GAA (0.35) GAAL3MBTL1HCRTR1MMP12MMP13
SCHEMBL25978971 0.98 PLA2G2A (0.35) GAAL3MBTL1HCRTR1MMP12MMP13
SCHEMBL26779128 0.98 PLA2G2A (0.35) GAAL3MBTL1HCRTR1MMP12MMP13
SCHEMBL25979407 0.97 L3MBTL1 (0.37) GAAL3MBTL1HCRTR1MMP12MMP13
SCHEMBL25979224 0.96 PLA2G2A (0.36) GAAL3MBTL1HCRTR1MMP12MMP13
SCHEMBL24574979 0.96 ALDH1A1 (0.35) GAAL3MBTL1MMP12MMP13PGR
SCHEMBL25979307 0.96 ALDH1A1 (0.35) GAAL3MBTL1MMP12MMP13PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
EP-4227301-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 GAA 2319/4885L3MBTL1 1367/4885HCRTR1 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.